THE VALUE OF LOWERING CHOLESTEROL AFTER MYOCARDIAL-INFARCTION

被引：365

作者：

ROSSOUW, JE

LEWIS, B

RIFKIND, BM

机构：

[1] NHLBI, LIPID METAB ATHEROGENESIS BRANCH, FED BLDG, RM 401, BETHESDA, MD 20892 USA

[2] ST THOMAS HOSP, RAYNE INST, LONDON SE1 7EH, ENGLAND

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 1990年 / 323卷 / 16期

关键词：

D O I：

10.1056/NEJM199010183231606

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CURRENT recommendations for lowering the cholesterol level to prevent coronary heart disease have focused largely on primary prevention and have paid less attention to the issue of lowering cholesterol in patients who already have coronary disease.1 2 3 4 5 6 It remains a common conception that in survivors of infarction the extent of myocardial damage is the prime determinant of outcome and serum cholesterol is not a major risk factor.7 The opposing view is that the modifiable risk factors after a myocardial infarction are the same as those before and merit treatment.8,9 In current practice, it appears that most patients with coronary disease do. © 1990, Massachusetts Medical Society. All rights reserved.

引用

页码：1112 / 1119

页数：8

共 64 条

[1] PREVALENCE OF ISCHEMIC RESTING AND STRESS ELECTROCARDIOGRAPHIC ABNORMALITIES AND ANGINA AMONG 40-YEAR-OLD TO 59-YEAR-OLD MEN IN SELECTED UNITED-STATES AND USSR POPULATIONS [J].

ABERNATHY, JR ;

THORN, MD ;

TROBAUGH, GB ;

EKELUND, LG ;

MACIOLOWSKI, M ;

LUPOVETSKY, B ;

SHELNOVA, S ;

ZHUKOVSKY, G ;

SHESTOV, D ;

DEEV, A .

CIRCULATION, 1988, 77 (02) :270-278

[2]

[Anonymous], 1965, LANCET, V2, P501

[3]

[Anonymous], 1968, LANCET, V2, P693

[4]

[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360

[5] DIET, LIPOPROTEINS, AND THE PROGRESSION OF CORONARY ATHEROSCLEROSIS - THE LEIDEN INTERVENTION TRIAL [J].

ARNTZENIUS, AC ;

KROMHOUT, D ;

BARTH, JD ;

REIBER, JHC ;

BRUSCHKE, AVG ;

BUIS, B ;

VANGENT, CM ;

KEMPENVOOGD, N ;

STRIKWERDA, S ;

VANDERVELDE, EA .

NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (13) :805-811

[6]

BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080

[7] BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS [J].

BLANKENHORN, DH ;

NESSIM, SA ;

JOHNSON, RL ;

SANMARCO, ME ;

AZEN, SP ;

CASHINHEMPHILL, L .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23) :3233-3240

[8] EFFECTS OF THERAPY WITH CHOLESTYRAMINE ON PROGRESSION OF CORONARY ARTERIOSCLEROSIS - RESULTS OF THE NHLBI TYPE-II CORONARY INTERVENTION STUDY [J].

BRENSIKE, JF ;

LEVY, RI ;

KELSEY, SF ;

PASSAMANI, ER ;

RICHARDSON, JM ;

LOH, IK ;

STONE, NJ ;

ALDRICH, RF ;

BATTAGLINI, JW ;

MORIARTY, DJ ;

FISHER, MR ;

FRIEDMAN, L ;

FRIEDEWALD, W ;

DETRE, KM ;

EPSTEIN, SE .

CIRCULATION, 1984, 69 (02) :313-324

[9] 15 YEAR MORTALITY IN CORONARY DRUG PROJECT PATIENTS - LONG-TERM BENEFIT WITH NIACIN [J].

CANNER, PL ;

BERGE, KG ;

WENGER, NK ;

STAMLER, J ;

FRIEDMAN, L ;

PRINEAS, RJ ;

FRIEDEWALD, W .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) :1245-1255

[10]

CARLSON LA, 1988, ACTA MED SCAND, V223, P405

← 1 2 3 4 5 6 7 →